European Union - English - EMA (European Medicines Agency)

shionogi b.v. - lusutrombopag - thrombocytopenia - antihemorrhagics - mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

United States - English - NLM (National Library of Medicine)

shionogi inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen 375 mg - carefully consider the potential benefits and risks of naprelan®  tablets and other treatment options before deciding to use naprelan®  tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naprelan®  tablets are indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout. it is also indicated in the relief of mild to moderate pain and the treatment of primary dysmenorrhea. naprelan®  is contraindicated in patients with known hypersensitivity to naproxen. naprelan®  should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings- anaphylactoid reactions, and precautions- preexisting asthma). naprelan®  is contraindicated for the treatment of peri-operative pain in the setting of corona

European Union - English - EMA (European Medicines Agency)

shionogi b.v. - naldemedine tosilate - constipation - drugs for constipation, peripheral opioid receptor antagonists - rizmoic is indicated for the treatment of opioid-induced constipation (oic) in adult patients who have previously been treated with a laxative.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - metreleptin (genetical recombination) - white and clumped injectable preparation

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - morphine hydrochloride hydrate - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - morphine hydrochloride hydrate - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - morphine hydrochloride hydrate - injection

United States - English - NLM (National Library of Medicine)

shionogi inc. - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of ponstel and other treatment options before deciding to use ponstel. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). ponstel is indicated: - for relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. ponstel is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings; anaphylactic reaction, exacerbation of asthma related to aspirin sensit

United States - English - NLM (National Library of Medicine)

shionogi inc. - naldemedine tosylate (unii: v1n8f1rvvo) (naldemedine - unii:03ksi6wlxh) - symproic is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. symproic is contraindicated in: - patients with known or suspected gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation [see warnings and precautions (5.1)]. - patients with a history of a hypersensitivity reaction to naldemedine. reactions have included bronchospasm and rash [see adverse reactions (6.1)] . risk summary there are no available data with naldemedine in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. there is a potential for opioid withdrawal in a fetus when symproic is used in pregnant women [see

United States - English - NLM (National Library of Medicine)

shionogi inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg in 5 ml - methylin is indicated for the treatment of: - attention deficit hyperactivity disorder (adhd) in adults and pediatric patients 6 years of age and older - narcolepsy methylin is contraindicated in patients: - with known hypersensitivity to methylphenidate or other components of methylin. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [see adverse reactions (6)] . - receiving concomitant treatment with monoamine oxidase inhibitors (maois), or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [see drug interactions (7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including methylin, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychostimulants at 1-866-961-2388. risk summary published studies